Insmed Incorporated (LON:0JAV)

Market Cap	23.20B +108.6%
Revenue (ttm)	332.56M +30.3%
Net Income	-880.70M
EPS	-4.63
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	469
Average Volume	735
Open	148.48
Previous Close	146.64
Day's Range	142.99 - 150.00
52-Week Range	61.28 - 214.00
Beta	1.12
RSI	29.02
Earnings Date	Feb 19, 2026

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 1,271
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JAV

Financial Performance

In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.

Financial numbers in USD